logo

Agile Therapeutics Inc. (AGRX)



Trade AGRX now with
  Date
  Headline
12/22/2017 7:31:56 AM Agile Gets Complete Response Letter From FDA For Twirla For Prevention Of Pregnancy
10/31/2017 7:47:39 AM Agile Presents Addl Phase 3 SECURE Trial Results For Twirla At American Society For Reproductive Medicine
10/16/2017 7:46:32 AM Agile Therapeutics Presents Additional Twirla Phase 3 SECURE Study Results At NAFFP 2017
9/14/2017 7:10:23 AM RBC Capital Markets Is Increasing Agile Therapeutics Inc. (AGRX) 4Q18 Estimate To -0.23 From -0.28
9/14/2017 7:10:08 AM RBC Capital Markets Is Increasing Agile Therapeutics Inc. (AGRX) 3Q18 Estimate To -0.24 From -0.25
9/14/2017 7:09:47 AM RBC Capital Markets Is Cutting Agile Therapeutics Inc. (AGRX) 2019 Rev. Estimate To 92.6 M From 105.8 M
9/14/2017 7:09:33 AM RBC Capital Markets Is Lowering Agile Therapeutics Inc. (AGRX) 2018 Rev. Estimate To 18.8 M From 52.6 M
9/14/2017 7:08:57 AM RBC Capital Markets Is Lowering Agile Therapeutics Inc. (AGRX) 2019 Estimate To 0.52 From 0.82
9/14/2017 7:08:41 AM RBC Capital Markets Is Cutting Agile Therapeutics Inc. (AGRX) 2018 Estimate To -1.02 From -0.40
8/3/2017 8:25:11 AM Agile Therapeutics Announces Pricing Of Public Offering Of 5.33 Mln Shares At $3.75/Shr
7/28/2017 7:40:37 AM Agile Therapeutics Q2 Net Loss $7.4 Mln Or $0.26 Per Share